Affimed (NASDAQ:AFMD) Short Interest Update

Affimed (NASDAQ:AFMD) was the target of a significant growth in short interest in the month of April. As of April 15th, there was short interest totalling 219,400 shares, a growth of 11.7% from the March 31st total of 196,400 shares. Approximately 1.7% of the shares of the company are sold short. Based on an average trading volume of 91,100 shares, the short-interest ratio is currently 2.4 days.

Wall Street Analysts Forecast Growth

AFMD has been the topic of several recent research reports. Cantor Fitzgerald reiterated an “overweight” rating on shares of Affimed in a research report on Monday, April 1st. StockNews.com began coverage on shares of Affimed in a research note on Tuesday, January 2nd. They issued a “sell” rating for the company. HC Wainwright increased their price objective on shares of Affimed to $10.00 and gave the stock a “buy” rating in a research note on Monday, April 1st. Finally, Wells Fargo & Company reduced their price objective on shares of Affimed from $30.00 to $25.00 and set an “overweight” rating for the company in a research note on Monday, April 1st. One research analyst has rated the stock with a sell rating and five have given a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $45.00.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. EWA LLC purchased a new stake in shares of Affimed in the fourth quarter worth about $89,000. abrdn plc purchased a new stake in shares of Affimed during the 4th quarter worth approximately $130,000. Vestal Point Capital LP bought a new position in shares of Affimed during the 4th quarter valued at approximately $341,000. Finally, BNP Paribas Financial Markets grew its holdings in shares of Affimed by 39.9% in the fourth quarter. BNP Paribas Financial Markets now owns 571,975 shares of the biopharmaceutical company’s stock valued at $357,000 after purchasing an additional 163,162 shares in the last quarter. Institutional investors own 30.82% of the company’s stock.

Affimed Stock Performance

Shares of NASDAQ AFMD opened at $5.35 on Wednesday. The firm has a fifty day moving average price of $5.44 and a 200-day moving average price of $5.04. The company has a debt-to-equity ratio of 0.11, a current ratio of 3.25 and a quick ratio of 3.23. The stock has a market cap of $81.48 million, a PE ratio of -0.64 and a beta of 2.05. Affimed has a 1 year low of $2.23 and a 1 year high of $11.10.

Affimed Company Profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and Europe. Its lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase II clinical trial for hodgkin lymphoma, and completed Phase II clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia.